




Adjusted First-Year Death Rates: Incident ESRD Patients




Adjusted First-Year Death Rates: By Treatment Modality




Impact of Age on Mortality among New ESRD Patients




Impact of Race on Survival of New ESRD Patients




Cardiovascular Conditions among New ESRD Patients




Left Ventricular Hypertrophy in Chronic Kidney Disease




Mortality Impact of Cardiovascular Conditions among new ESRD




Impact of Baseline BMI and Changes over 6-months on Mortality




Impact of Baseline Albumin and Changes over 6-months on Mortality




Impact of Serum Creatinine and Changes over 6-months on Mortality




C-Reactive Protein and Mortality Risk in Hemodialysis



Impact of Neutrophil Count and Changes over 6 mths with Mortality Risk




Mortality Risks By Vascular Type among U.S. Hemodialysis Patients




CVC= central venous Catheter; AVG=arteriovenous graft; AVF=arteriovenous fistula

Arteriovenous Fistula use among Incident Patients: Europe vs U.S.A.



First Consult with a Nephrologist prior to ESRD Start: DMMS W2 Study




Mortality Risk: Late vs Early Referral in new ESRD patients


Adjustment	RR 1-year	(95% CI)
Unadjusted	1.57	(1.25-1.98)
+ Demographic	1.57	(1.25-1.98)
+ Comorbid	1.68	(1.31-2.15)
+ pre-ESRD factors ¹	1.66	(1.28-2.16)

¹Also adjusted for exercise level, erythropoietin use, visits to a dietitian


Ca⁺⁺ Channel Blockers, HMG- CoA Reductase Inhibitors and Mortality



Prevalence of ACE Inhibitor Use by Cardiac Condition



Prevalence of Beta-Blocker Use by Cardiac Condition



The Optimal pre-End-stage Kidney Disease (ESRD) Plan

